Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies Read More »
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7%. Xenon Pharmaceuticals believes this is the highest such efficacy “observed in a pivotal epilepsy study,” CEO Ian Mortimer said Monday.
Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset giredestrant was unsuccessful.
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall Read More »
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site Read More »
Some biotechs that had seen regulatory setbacks under Center for Biologics Evaluation and Research director Vinay Prasad experienced stock bumps Monday morning. Under Prasad’s leadership, the rare disease space has suffered a series of controversial rejections.
Prasad’s Departure Could Be ‘Big Win’ For Biotech—Especially Rare Disease Space: Stifel Read More »
The FDA’s cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months Read More »
Se ha descubierto un mecanismo que permite a las células eliminar proteínas dañadas sin consumir energía para ello. Este hallazgo abre la puerta a futuras estrategias clínicas para evitar la acumulación de proteínas defectuosas, algunas de ellas …
Descubren un mecanismo que permite a las células degradar proteínas sin consumir energía Read More »
Noticias de la actualidad astronómica y astronáutica del 9 de marzo de 2026. …
Una investigación reciente ha sacado a la luz detalles perturbadores de los restos mortales de decenas de personas que fueron sepultadas en una fosa común en Gomolava, en el norte de Serbia, hace aproximadamente 2800 años, durante la Edad del Hierro. El estudio lo ha re …
Hoy te proponemos repasar algunas claves cruciales para responder una de las preguntas más comunes cuando se trata de hacer tu casa más cómoda. En realidad, la decisión influye mucho en el ambiente familiar y en cuánto terminarás pagando de facturas mes tras …
Aerotermia o aire acondicionado: qué sistema de climatización elegir para tu hogar Read More »
